

## 2007 HALF-YEAR FINANCIAL REPORT

**Paris, August 31, 2007** - CEGEDIM, the world's leading provider of CRM (Customer Relationship Management) solutions specifically designed for the pharmaceutical industry, today announces the publication of its 2007 half-year financial report on its web site.

The CEGEDIM Group has decided to publish a purely narrative financial report for the first half of 2007, within two months of the close of the period, in compliance with the 16 October 2006 guidelines of the *Autorité de Marchés Financiers* (AMF). Neither the consolidated half-year results, nor the statement by the person responsible for the financial information, nor the Statutory Auditors report are included in this document.

The figures cited in this report will be subject to a limited review by the Statutory Auditors as part of the publication of the half-year results planned for the end of October 2007.

This report is issued pursuant to article 221-3 of the AMF's General Rules and Regulations. It is notably available on the Company's website at [www.cegedim.com](http://www.cegedim.com), under the heading Investors/Financial Information.

### **About CEGEDIM:**

CEGEDIM has been developing exclusive databases and high value added software solutions since 1969.

Established as the world's leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). Its Cegedim Strategic Data and Cegedim Customer Information activities are also dedicated to pharmaceutical companies and help them improve sales & marketing effectiveness thanks to the Group's strategic databases focused on the world drug market.

This expertise falls into the "Healthcare and strategic data" division of the CEGEDIM Group, which comprises the services specifically designed for pharmaceutical companies cited above and specific solutions dedicated to healthcare professionals (notably physicians and pharmacists in Europe) and health insurance providers.

The "Technologies and services" division capitalizes on the Group's technical skills in order to provide specific solutions to clients of various sectors, essentially in France.

CEGEDIM generated turnover of €541 million in 2006. Including Dendrite, the 2006 cumulated revenue would amount to €877 million for a workforce of 7,500 and operations in more than 80 countries. To learn more, please see our website: [www.cegedim.com](http://www.cegedim.com)

Listed on Eurolist by Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

---

**Media inquiries****CEGEDIM**

Aude Balleydier  
Media Relations  
Tel: + 33 (0)1 49 09 68 81  
[aude.balleydier@cegedim.fr](mailto:aude.balleydier@cegedim.fr)

**VP COMMUNICATION**

Coralie Voigt  
Press Officer  
Tel: + 33 (0)1 40 22 04 01  
[cvoigt@vp-communication.com](mailto:cvoigt@vp-communication.com)

**Investor relations****CEGEDIM**

Sandrine Debroise  
Chief Financial Officer  
Tel: + 33 (0)1 49 09 22 00  
[investor.relations@cegedim.fr](mailto:investor.relations@cegedim.fr)